Results 141 to 150 of about 73,068 (324)
Paraganglioma in the bladder: a case report
Journal of Medical Case Reports, 2017 Background Paraganglioma is an extra site of pheochromocytoma. Paraganglioma in the bladder is a very rare disease accounting for 0.06% of all bladder tumors.
Genta Iwamoto +13 more
doaj +1 more source
Genetic mutation screening in an Italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients [PDF]
, 2006 To assess the prevalence of genetic mutations in nonsyndromic pheochromocytoma/paraganglioma (PHEO/PGL) patients we have performed a systematic search for mutations in the succinate dehydrogenase (SDH) B, C, and D subunits, von Hippel-Lindau (VHL), and ...
AGABITI ROSEI E +10 more
core
Cancers, 2019 Low-specific-activity iodine-131–radiolabeled metaiodobenzylguanidine (I-131-MIBG) was introduced last century as a potential systemic therapy for patients with malignant pheochromocytomas and paragangliomas.
C. Jimenez, W. Erwin, B. Chasen
semanticscholar +1 more source
Internal Medicine, 2019 A 57-year-old woman was admitted with lower abdominal pain and bloody bowel discharge. She was diagnosed with rectal tumor by colonoscopy, and a biopsy was performed. Surgery was performed, resulting in a diagnosis of rectal paraganglioma. Since recurrence was confirmed three years later, reoperation was done, and chemotherapy with cyclophosphamide ...
Araki, Tomonori +6 more
openaire +3 more sources
Medicinal Research Reviews, Volume 46, Issue 1, Page 203-237, January 2026.ABSTRACT Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 (211At) has experienced increased interest due to its favorable decay properties.
Marius Müller +5 more
wiley +1 more source
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients [PDF]
, 2011 Neuroendocrine tumors (NETs) can be sporadic or they can arise in complex hereditary syndromes. Patients with hereditary NETs can be identified before the development of tumors by performing genetic screenings.
COLAO, ANNAMARIA +9 more
core +1 more source
Paraganglioma of the head and neck: A Review.
Endocrine Practice, 2022 Lyndsey Sandow +3 more
semanticscholar +1 more source
Differential loss of chromosome 11q in familial and sporadic parasympathetic paragangliomas detected by comparative genomic hybridization [PDF]
, 2001 Parasympathetic paragangliomas (PGLs) represent neuroendocrine tumors arising from chief cells in branchiomeric and intravagal paraganglia, which share several histological features with their sympathetic counterpart ...
Dannenberg, H. (Hilde) +9 more
core +2 more sources
Molecular imaging and radionuclide therapy of paraganglioma and pheochromocytoma.
Endocrine-Related Cancer, 2019 In recent years, advancement in genetics has profoundly helped to gain a more comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and paragangliomas (PPGLs).
D. Taieb +3 more
semanticscholar +1 more source
Clinical and Translational Science, Volume 19, Issue 1, January 2026.ABSTRACT Clinical genomics and pharmacogenomics have largely remained separate fields, though some genetic variants have overlapping disease risk and drug implications. However, the extent of this overlap is not well studied. To explore this gap, we cross‐referenced genes from the American College of Medical Genetics Secondary Findings v3.2 list with ...
Josiah D. Allen +3 more
wiley +1 more source